Key Development
South Korean biopharmaceutical major Samsung Bioepis Co., Ltd. officially announced the commercial availability of the pre-filled syringe (PFS) $40\text{ mg/mL}$ presentation of its aflibercept biosimilar, Opuviz® (referencing Regeneron/Bayer’s Eylea®), across European markets effective August 10, 2026.
The launch marks a key portfolio milestone, complementing the commercial rollout of the product’s vial presentation introduced across Europe in May 2026.
Product Architecture & EU Authorized Indications:
-
Presentation: Single-dose, ready-to-use $40\text{ mg/mL}$ solution in a pre-filled syringe designed for intravitreal administration.
-
Approved Therapeutic Indications: Authorized for adult patients across four major retinal conditions:
-
Neovascular (wet) age-related macular degeneration (AMD).
-
Visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
-
Visual impairment due to diabetic macular edema (DME).
-
Visual impairment due to myopic choroidal neovascularization (myopic CNV).
-
-
Regulatory History: Initial European Commission (EC) marketing authorization for the vial presentation was secured in November 2024. The PFS presentation received a positive CHMP opinion in November 2025 prior to its commercial launch.
Why It Matters
-
Enhanced Convenience & Dosing Precision for Ophthalmologists: Unlike traditional vial presentations that require manual withdrawal and dose calibration, the pre-filled syringe offers a ready-to-use delivery system that streamlines clinical workflows, improves dosing accuracy, and minimizes potential contamination risks during intravitreal administration.
-
Heightened Competition Against Reference Eylea®: Aflibercept represents a leading anti-VEGF biologic globally. Introducing a user-friendly PFS format enables higher clinical adoption, fostering cost-efficiency across European healthcare systems.
-
Execution of Settlement Framework: The commercial launch follows the global settlement and licensing agreement finalized between Samsung Bioepis, Regeneron, and Bayer in early 2026 concerning European aflibercept biosimilar IP.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the August 10, 2026 European launch of Opuviz® PFS exemplifies Ophthalmology Biosimilar Convenience Standards.
Within the intravitreal anti-VEGF sector, device delivery mechanics heavily influence clinical preference. Ophthalmologists across European retinal clinics overwhelmingly favor pre-filled syringes due to operational speed and safety advantages. Competing solely with vial formats restricts biosimilar conversion rates from originator biologics.
Rapidly deploying the PFS presentation following the vial launch delivers strategic benefits:
-
Strengthening Direct Commercial Infrastructure: Samsung Bioepis solidifies its direct commercialization posture in Europe, building upon its existing retina portfolio, which includes Byooviz® (ranibizumab).
-
Competitive Differentiation Among Biosimilar Entrants: Securing early PFS market availability positions Opuviz® ahead of rival aflibercept biosimilars navigating regulatory approvals for syringe formats.
Market Implications
-
Accelerating Clinical Conversion in European Retina Centers: Retina specialists gain immediate access to a cost-effective, high-precision anti-VEGF option, supporting broader patient access under national health frameworks.
-
Revenue Driver for Samsung Bioepis’ Biosimilar Vertical: Opuviz® PFS will serve as a primary top-line commercial driver for Samsung Bioepis in Europe throughout H2 2026.
-
Commercial Pressure on Originator Eylea® Volume: The availability of Opuviz® PFS will accelerate volume erosion for legacy $2\text{ mg}$ Eylea® formulations across EU member states.
Product Profile Matrix: Opuviz® (Aflibercept Biosimilar) Europe
| Product Parameter | Technical & Regulatory Specifications | Clinical & Commercial Impact |
| Active Substance | Aflibercept (Recombinant VEGF inhibitor) | Inhibits abnormal ocular angiogenesis and vascular leakage. |
| New Presentation | Pre-Filled Syringe (PFS) $40\text{ mg/mL}$ | Available from August 10, 2026; enhances dosing accuracy. |
| Prior Presentation | Single-use Vial $40\text{ mg/mL}$ | Commercialized across Europe in May 2026. |
| Regulatory Clearance | European Commission (EC) / EMA | Approved Nov 2024 (Vial) & CHMP Nov 2025 (PFS). |
| Target Indications | Wet AMD, DME, RVO, Myopic CNV | Covers all primary adult ophthalmic indications of Eylea®. |
Source: https://biovoicenews.com/samsung-bioepis-opuviz-prefilled-syringe-europe/